Luis G. Ortega Paz, M.D.

Luis G. Ortega Paz M.D.

Assistant Professor

Department: Department of Medicine
Business Phone: (904) 244-2060
Business Email:

About Luis G. Ortega Paz

Luis G. Ortega Paz, M.D., is an academic cardiologist. He was trained in cardiovascular diseases at the Cardiovascular Institute of the Hospital Clínic of Barcelona at the University of Barcelona. His primary research topics are clinical trials, antiplatelet therapy, platelet biology, acute coronary syndromes, and COVID-19-associated cardiovascular complications. He has published over 75 articles in indexed journals and five book chapters. He has been an investigator of several randomized clinical trials and prospective registries. He has presented lectures, oral communications, and Late-breaking clinical trials at international congresses. He obtained his Ph.D. degree in medicine and translational research program from the University of Barcelona. He is a professional member of the European Society of Cardiology, ESC thrombosis working group, and the European Interventional Cardiology Society. He is a member of the editorial team of EuroIntervention journal (section editor) and a peer reviewer for top cardiovascular medical journals.

Clinical Profile

  • Cardiovascular Disease
  • Clinical Special Interests: antiplatelet therapy, bleeding avoidance strategies, acute coronary syndromes, metabolic syndromes, and COVID-19-associated cardiovascular complications.
  • Research Special Interests: Clinical trials, cardiovascular pharmacotherapy, acute coronary syndromes, bleeding avoidance strategies, lipid-lowering therapies, antidiabetic drugs, and COVID-19-associated cardiovascular complications.
  • Speaks English and Spanish


Oral P2Y12 inhibiting therapy in patients with acute coronary syndrome: finding the sweet spot
European Heart Journal.44(3):236-236[DOI] 10.1093/eurheartj/ehac601.[PMID] .
Sex Differences in 10-Year Outcomes After Percutaneous Coronary Intervention With Drug-Eluting Stents: Insights From the DECADE Cooperation
Circulation.147(7):575-585[DOI] 10.1161/circulationaha.122.062049.[PMID] .
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions.16(20):2528-2539[DOI] 10.1016/j.jcin.2023.08.009.[PMID] .
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study
Thrombosis and Haemostasis.():-[DOI] 10.1055/a-2098-6639.[PMID] .
Impact of Diabetes on 10‐Year Outcomes Following ST‐Segment–Elevation Myocardial Infarction: Insights From the EXAMINATION‐EXTEND Trial
Journal of the American Heart Association.11(23):-[DOI] 10.1161/jaha.122.025885.[PMID] .
Mid-term effects of SARS-CoV-2 infection on cardiovascular outcomes
Medicina Clínica.158(1):41-42[DOI] 10.1016/j.medcli.2021.05.006.[PMID] 34147251.
Mid-term effects of SARS-CoV-2 infection on cardiovascular outcomes
Medicina Clínica (English Edition).158(1):41-42[DOI] 10.1016/j.medcle.2021.05.008.[PMID] 35018305.
P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention
Journal of Cardiovascular Development and Disease.9(10):340-[DOI] 10.3390/jcdd9100340.[PMID] 36286292.
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
European Heart Journal - Cardiovascular Pharmacotherapy.8(7):677-686[DOI] 10.1093/ehjcvp/pvab070.[PMID] 34519777.
Acute and Chronic Effects of COVID-19 on the Cardiovascular System
Journal of Cardiovascular Development and Disease.8(10):128-[DOI] 10.3390/jcdd8100128.[PMID] 34677197.
Canakinumab for secondary prevention of coronary artery disease
Future Cardiology.17(3):427-442[DOI] 10.2217/fca-2020-0211.[PMID] .
Coronary Endothelium‐Dependent Vasomotor Function After Drug‐Eluting Stent and Bioresorbable Scaffold Implantation
Journal of the American Heart Association.10(22):-[DOI] 10.1161/jaha.121.022123.[PMID] .
Coronavirus Disease 2019–Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management
Journal of the American Heart Association.10(3):-[DOI] 10.1161/jaha.120.019650.[PMID] .
Myocardial Injury in COVID-19 Patients: Association with Inflammation, Coagulopathy and In-Hospital Prognosis
Journal of Clinical Medicine.10(10):2096-[DOI] 10.3390/jcm10102096.[PMID] 34068127.
Very-late restenosis of a magnesium-based resorbable scaffold
European Heart Journal.41(27):2602-2602[DOI] 10.1093/eurheartj/ehaa391.[PMID] .
Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial
EuroIntervention.13(16):1939-1945[DOI] 10.4244/eij-d-17-00608.[PMID] .
Impact of PSP Technique on Clinical Outcomes Following Bioresorbable Scaffolds Implantation
Journal of Clinical Medicine.7(2):27-[DOI] 10.3390/jcm7020027.[PMID] 29415486.
Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION [Evaluation of the Xience-V Stent in Acute Myocardial Infarction] Trial)
The American Journal of Cardiology.121(9):1039-1045[DOI] 10.1016/j.amjcard.2018.01.015.[PMID] .
TIcaGrEloR and Absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization (TIGER-BVS trial): Rationale and study design
Catheterization and Cardiovascular Interventions.91(1):1-6[DOI] 10.1002/ccd.27196.[PMID] .
Bioresorbable scaffolds: should we stay simple or go complex?
Cardiovascular Diagnosis and Therapy.7(3):E7-E12[DOI] 10.21037/cdt.2017.01.07.[PMID] 28567366.
Cardiac Magnetic Resonance as an Alternative to Endomyocardial Biopsy to Predict Recoverability of Left Ventricular Function in Methamphetamine- Associated Cardiomyopathy
JACC: Heart Failure.5(11):853-854[DOI] 10.1016/j.jchf.2017.08.009.[PMID] .
Complicaciones cardiacas graves por shabu: una droga emergente en Europa
Revista Española de Cardiología.70(11):1014-1016[DOI] 10.1016/j.recesp.2016.11.050.[PMID] .
Data from real-world registries: can it guide development of the bioresorbable scaffolds of tomorrow?
EuroIntervention.13(11):1259-1262[DOI] 10.4244/eijv13i11a197.[PMID] .
Endothelial function impairment in STEMI patients with out-of-hospital cardiac arrest under therapeutic hypothermia treatment
International Journal of Cardiology.232():70-75[DOI] 10.1016/j.ijcard.2017.01.050.[PMID] .
Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST–Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation
The American Journal of Cardiology.120(9):1460-1466[DOI] 10.1016/j.amjcard.2017.07.040.[PMID] .
Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry
Catheterization and Cardiovascular Interventions.89(5):812-818[DOI] 10.1002/ccd.26674.[PMID] .
Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: insights from the five-year follow-up of the EXAMINATION trial
EuroIntervention.13(5):e557-e563[DOI] 10.4244/eij-d-16-00512.[PMID] .
miRNA Update: A Review Focus on Clinical Implications of miRNA in Vascular Remodeling
AIMS Medical Science.4(1):99-112[DOI] 10.3934/medsci.2017.1.99.[PMID] .
Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score
EuroIntervention.12(17):2110-2117[DOI] 10.4244/eij-d-16-00974.[PMID] .
Rationale and design of the Hunting for the off-target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial
American Heart Journal.189():128-136[DOI] 10.1016/j.ahj.2017.03.017.[PMID] .
Serial optical coherence tomography assessment of malapposed struts after everolimus-eluting stent implantation. A subanalysis from the HEAL-EES study
Cardiovascular Revascularization Medicine.18(1):47-52[DOI] 10.1016/j.carrev.2016.08.010.[PMID] .
ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison
International Journal of Cardiology.214():483-484[DOI] 10.1016/j.ijcard.2016.04.016.[PMID] .
Bioresorbable vascular scaffolds technology: current use and future developments
Medical Devices: Evidence and Research.Volume 9():185-198[DOI] 10.2147/mder.s90461.[PMID] .
Could Plaque Composition-Related Endothelial Dysfunction Predict Poor Prognosis in Coronary Vasospastic Angina?
Journal of the American College of Cardiology.67(15):1867-[DOI] 10.1016/j.jacc.2015.12.070.[PMID] .
Five-Year Optical Coherence Tomography in Patients With ST-Segment–Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents
Circulation: Cardiovascular Interventions.9(10):-[DOI] 10.1161/circinterventions.116.003670.[PMID] .
Lesión miocárdica en consumidor de shabú: patrón multifocal de realce tardío de gadolinio
Medicina Clínica.147(12):570-[DOI] 10.1016/j.medcli.2016.07.034.[PMID] .
Optical coherence tomography: A pathway from research to clinical practice
Cardiovascular Revascularization Medicine.17(2):71-73[DOI] 10.1016/j.carrev.2016.02.009.[PMID] .
TCT-404 ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-year results from a propensity score matched comparison
Journal of the American College of Cardiology.68(18):B164-[DOI] 10.1016/j.jacc.2016.09.539.[PMID] .
TCT-419 Usefulness of a scoring system for predicting adverse cardiovascular events in patients undergoing everolimus-eluting bioresorbable scaffolds implantation: the PSP score
Journal of the American College of Cardiology.68(18):B169-B170[DOI] 10.1016/j.jacc.2016.09.554.[PMID] .
Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks
Advances in Interventional Cardiology.3(3):161-169[DOI] 10.5114/pwki.2015.54006.[PMID] 26677353.
Letter by Ortega-Paz et al Regarding Article, “East Asian Variant of Aldehyde Dehydrogenase 2 Is Associated With Coronary Spastic Angina: Possible Roles of Reactive Aldehydes and Implications of Alcohol Flushing Syndrome”
Circulation.132(24):-[DOI] 10.1161/circulationaha.115.018218.[PMID] .
Percutaneous Transcatheter Aortic Valve Implantation: A Review Focus on Outcomes and Safety
AIMS Medical Science.2(3):200-221[DOI] 10.3934/medsci.2015.3.200.[PMID] .
Pre-eclampsia/eclampsia and hepatic rupture
International Journal of Gynecology & Obstetrics.118(3):186-189[DOI] 10.1016/j.ijgo.2012.03.042.[PMID] .
Retinal detachment in association with pre-eclampsia, eclampsia, and HELLP syndrome
International Journal of Gynecology & Obstetrics.114(3):223-225[DOI] 10.1016/j.ijgo.2011.04.003.[PMID] .

Office Information

Academic Office
Ambulatory Care Center, 5th Floor
655 West 8th Street
Jacksonville, FL 32209
(904) 244-2060
Medical Secretary
Monica George
(904) 244-2060


Medical Degree
2010 · Universidad de Panama, Panama City, Panama
Cardiovascular Disease Fellowship
2018 · University of Barcelona, Barcelona, Spain